Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?
Giovanna Garufi(Agostino Gemelli University Polyclinic), Fabio Puglisi(University of Udine), Anna Ventriglia(University of Campania "Luigi Vanvitelli"), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Emilio Bria(Università Cattolica del Sacro Cuore), Mattia Garutti(Centro di Riferimento Oncologico), Grazia Arpino(University of Naples Federico II), Concetta Arcanà(ASST Melegnano e della Martesana), Antonio Doronzo(Ospedale di Rivoli), Sara Parola, Alessandra Fabi(Agostino Gemelli University Polyclinic), Giampaolo Tortora(University of Naples Federico II), Mario Giuliano(Regione Campania), Lucia Del Mastro(Ospedale Policlinico San Martino), Armando Orlandi(Agostino Gemelli University Polyclinic), Antonella Palazzo(Agostino Gemelli University Polyclinic), Luisa Carbognin(Agostino Gemelli University Polyclinic)
Cited by 20
Related Papers
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
|Journal of Clinical Oncology|2010|887
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830